Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PF-00562271

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
In this issue of Targeted Oncology, the BI 853520 investigators present three complementary studies of BI 853520 that investigate… Expand
Is this relevant?
2017
2017
Background/Aims: Istaroxime is a validated inotropic Na+/K+ ATPase inhibitor currently in development for the treatment of… Expand
Is this relevant?
2017
2017
Background/Aims: Istaroxime is a validated inotropic Na+/K+ ATPase inhibitor currently in development for the treatment of… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2013
2013
Docetaxel remains the standard-of-care for men diagnosed with metastatic castrate-resistant prostate cancer (CRPC). However, only… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Docetaxel remains the standard-of-care formen diagnosedwithmetastatic castrate-resistant prostate cancer (CRPC). However, only… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE PF-00562271 is a novel inhibitor of focal adhesion kinase (FAK). The objectives of this study were to identify the… Expand
Is this relevant?
2010
2010
3028 Background: FAK is a non-receptor tyrosine kinase that transduces signaling from integrins and growth factor receptors to… Expand
Is this relevant?
2008
2008
3534 Background: FAK transduces signaling from integrins and growth factors to modulate tumor cell invasion, proliferation and… Expand
Is this relevant?